Stockscreener 앱 받기
7.14
0.56%
0.04
시간 외 거래:
7.15
0.01
+0.14%
전일 마감가:
$7.10
열려 있는:
$7.17
하루 거래량:
70,187
Relative Volume:
1.60
시가총액:
$411.94M
수익:
$181.68M
순이익/손실:
$20.37M
주가수익비율:
20.43
EPS:
0.3495
순현금흐름:
$17.31M
1주 성능:
+1.13%
1개월 성능:
-2.72%
6개월 성능:
-14.18%
1년 성능:
-3.38%
1일 변동 폭
$7.1109
$7.25
1주일 범위
$6.89
$7.25
52주 변동 폭
$6.50
$9.35
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.14 | 403.28M | 181.68M | 20.37M | 17.31M | 0.3495 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | The Benchmark Company | Buy |
| 2024-07-03 | 개시 | Stifel | Buy |
| 2018-02-02 | 개시 | Chardan Capital Markets | Buy |
Kamada Ltd 주식(KMDA)의 최신 뉴스
Kamada Ltd (KMDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kamada Ltd (KMDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kamada Ltd (KMDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kamada Ltd (KMDA) Cash Flow - TradingKey
Kamada Ltd. Revenue Breakdown – NASDAQ:KMDA - TradingView
Kamada Ltd. (KMDA) Stock Analysis: Exploring an 86.78% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Kamada Ltd (KMDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kamada Ltd. (KMDA) Sees Slight Decline as Shares Test Key Support ZoneCall Dominated - dars.gov.et
Kamada stock trades steadily as plasma-derived therapies support revenue growth - Ad-hoc-news.de
Kamada stock holds at Buy as Benchmark cites $50M plasma deal - Investing.com UK
Kamada secures $50M plasma supply deal over three years By Investing.com - Investing.com Nigeria
Kamada Signs $50 Million Plasma Supply Agreement With Biopharmaceutical Firm - Moomoo
Kamada jumps on $50m source plasma dealGlobes - Globes - Israel Business News
Kamada (KMDA) Secures $50M Plasma Supply Agreement - GuruFocus
Kamada Signs Three-Year, $50 Million Plasma Supply Deal to Bolster Growth - TipRanks
Kamada secures $50M plasma supply deal over three years - Investing.com
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies - The Manila Times
Kamada Ltd. (NASDAQ: KMDA) signs three-year $50M plasma supply agreement - Stock Titan
Kamada’s centers plan ~50,000 liters of plasma each at full capacity - Stock Titan
Kamada signs three-year USD 50 million plasma supply agreement with biopharmaceutical company - Bitget
Uri Botzer Net Worth (2026) - GuruFocus
Kamada Showcases New CYTOGAM Data from 2026 ISHLT Meeting, Signaling Potential Uptick in Transplant Use - TipRanks
Kamada highlights study results on CYTOGAM in transplants - Investing.com UK
symbol__ Stock Quote Price and Forecast - CNN
Kamada highlights Cytogam study results - TipRanks
Kamada highlights study results on CYTOGAM in transplants By Investing.com - Investing.com South Africa
Kamada (KMDA) Presents Promising Cytogam Study Results at Global Conference - GuruFocus
[6-K] KAMADA LTD Current Report (Foreign Issuer) | KMDA SEC FilingForm 6-K - Stock Titan
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting - GlobeNewswire
How (KMDA) Movements Inform Risk Allocation Models - Stock Traders Daily
Enterprise value to EBITDA forward of Kamada Ltd. – NASDAQ:KMDA - TradingView
Price to earnings forward of Kamada Ltd. – NASDAQ:KMDA - TradingView
Price to earnings forward of Kamada Ltd – TASE:KMDA - TradingView
Enterprise value to EBIT forward of Kamada Ltd. – NASDAQ:KMDA - TradingView
Kamada Ltd outlines plasma-derived therapies strategy. Investor focus on specialty biologics pipelin - Ad-hoc-news.de
Kamada Ltd. Q1 2026 Earnings: EPS Misses Estimates, Stock Declines SlightlyPost-Earnings Reaction - dars.gov.et
Kamada Ltd. (KMDA) Holds Steady Near Support as Technical Indicators Suggest ConsolidationPairs Trade - dars.gov.et
Kamada Ltd. (KMDA) Holds Steady as Shares Trade Near Midpoint of RangeMax Pain Level - dars.gov.et
Trading Systems Reacting to (KMDA) Volatility - Stock Traders Daily
KMDAKamada Ltd Latest SEC Filings - Finviz
Kamada Ltd updates drug portfolio as Nasdaq-listed biopharma pursues growth - ad-hoc-news.de
Kamada (KMDA) Corporate Presentation Summary - Quartr
Daichi Kamada Contract Boost Gives Crystal Palace Sage Win - Read Crystal Palace
KMDA Q1 2026 Earnings: EPS Misses Estimates, Stock Gains SlightlyFull Year Guidance - dars.gov.et
Kamada Ltd Actuals & Estimates (NASDAQ:KMDA) - TradingView
Kamada eyed by Milan and Fiorentina as Crystal Palace midfielder linked with Serie A return - Football Italia
KMDA Forecast — Price Target — Prediction for 2027 - TradingView
Kamada Ltd. (KMDA) Posts Modest Gain as Shares Hold Above Key Support LevelOverbought Signal Alerts - dars.gov.et
KMDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Kamada Ltd (KMDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Daichi Kamada World Cup form gives Crystal Palace fresh momentum - Read Crystal Palace
Kamada Ltd (KMDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.08%
0.17%
자본화:
|
볼륨(24시간):